Who
Adam Crystal
President, R&D
Company insider
Files Form 4 as: President, R&D, Tango Therapeutics; Chief Medical Officer, C4 Therapeutics.
In numbers
- Trades disclosed
- 116
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $16.5M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 Feb 2021
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code M | $140K27,000 at $5.20 | filing |
| 1 Oct 2026filed 5 Oct 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $646K26,400 at $24.45 | filing |
| 1 Oct 2026filed 5 Oct 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K600 at $25.32 | filing |
| 1 Oct 2026filed 5 Oct 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code M | $140K27,000 at $5.20 | filing |
| 1 Sep 2026filed 3 Sep 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $604K27,000 at $22.37 | filing |
| 1 Sep 2026filed 3 Sep 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code M | $140K27,000 at $5.20 | filing |
| 1 Sep 2026filed 3 Sep 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $604K27,000 at $22.37 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code M | $140K27,000 at $5.20 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $141K5,267 at $26.79 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $594K21,733 at $27.35 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,000 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,000 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code M | $140K27,000 at $5.20 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $141K5,267 at $26.79 | filing |
| 3 Aug 2026filed 5 Aug 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $594K21,733 at $27.35 | filing |
| 1 Jul 2026filed 2 Jul 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code M | $140K27,000 at $5.20 | filing |
| 1 Jul 2026filed 2 Jul 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $576K19,629 at $29.34 | filing |
News
Tango Therapeutics Maps 2027 Phase 3 Trial After Promising Cancer Data;Stock Down In Pre-MarketTNGX · rttnews.com · 23 Oct 2026Tango Therapeutics Stock Tumbles 16% Despite 82% Response Rate in Pancreatic Cancer Combo Trial at ESMOTNGX · ibtimes.com.au · 23 Oct 2026Tango Therapeutics Just Improved On This 'Unprecedented' Cancer DrugTNGX · investors.com · 23 Oct 2026
0 headlines in the last 90 days name Adam Crystal; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.